Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCavendish Plc Regulatory News (CAV)

Share Price Information for Cavendish Plc (CAV)

Share Price is delayed by 15 minutes
Get Live Data
9.25    0.00 (0.00%)
Bid:
9.00
Ask:
9.50
Spread: 0.50 (5.556%)
Market Cap: £31.06m
CAV Live PriceLast checked at - London Stock Exchange

Intraday Cavendish Plc Share Chart

Total Voting Rights

26 Jul 2024 07:00

RNS Number : 9173X
Cavendish Financial PLC
26 July 2024
 

26 July 2024

Cavendish Financial plc

("Cavendish", the "Company" or the "Group")

Total Voting Rights

Cavendish Financial plc (AIM:CAV) today announces the results of an offer (the "July Offer") made under its Co-Investment Plan ("CIP"), which was launched in February 2024, following issue of the Company's full-year results to 31 March 2024 and as signalled in the announcement of the launch of the CiP on 19 February 2024.

The July Offer (to acquire, out of their own post-tax funds, ordinary shares in Cavendish at the prevailing market price through a one-off lump sum subscription (the "CiP Shares")) was made to new joiners and employees newly promoted to Director since the first CiP offer, as well as to other eligible employees who were not able to participate in the first offer, or who had expressed a desire to top up their initial investment.

The CiP Shares will be held by the trustee of the Company's employee benefit trust, as nominee for the participants, subject to a 3-year lock up, but will rank for dividends and voting rights alongside other ordinary shares during this time. In accordance with the Rules of the CiP, additional shares ("Additional Shares") will be awarded to the participants based on the number of CiP Shares they acquired and the satisfaction of the following share price targets. The Target Base Price was 11.75p per share being the closing share price on 16 July 2024, the business day immediately before formal offers to participate were issued to eligible employees:

Premium to Target Base Price

Corresponding target share price

Additional Shares awarded for each CiP Share acquired

Less than 20.5p

0.5

>=75%

20.5p

2

>=125%

26.4p

3

>=175%

32.3p

4

 

The target share prices include dividends paid over the duration of the CiP and will be assessed on a 20-day VWAP basis, in the 20 dealing days prior to the end of the 3-year lock up period. 

Shares will also be awarded if any of the above hurdles are met on a 90-day VWAP basis at any time during the 3-year lock up period, but will only be received by employees at the end of that period and subject, inter alia, to continued employment (other than in certain good leaver circumstances). Where both the 20-day VWAP and 90-day VWAP targets are met, participants will receive the highest number of shares payable of the two. Only one grant of additional shares can be awarded.

In aggregate, employees participating in the July Offer have contributed £127,000 for the subscription of new ordinary shares in Cavendish at 12.75p per share (the closing market price on 25 July 2024). 

Accordingly, Cavendish has raised £127,000 of new capital through the issue of 996,072 new ordinary shares of 1 pence each under the CiP, which shares were issued and allotted on 25 July 2024 to the trustee of the Company's employee benefit trust, Ogier Global Trustee (Jersey) Limited, in its capacity as nominee on behalf of participants. 

The Company has applied for admission of these newly issued and allotted shares to trading on AIM. Admission is expected to take place at 8.00 a.m. on 1 August 2024.

Subject to the rules of the CiP, (a summary of which has been previously announced), and all participants remaining in the CiP until the end of the 3-year lock up period, the estimated number of Additional Shares that may be allotted under the July Offer if (i) the minimum share price target is achieved, is c.0.5m new ordinary shares (c.0.1% of Cavendish's issued share capital, post the allotment announced today) and (ii) if the maximum share price target is achieved, is c.3.9m new ordinary shares (c.1.03% of Cavendish's issued share capital, post the allotment announced today).

As previously stated, Cavendish intends to manage the overall shareholder dilution of the CiP through funding its EBT to make market purchases over time with the intention of limiting the ultimate overall dilution from share option and employee incentive plans to less than c.15% of the total issued share capital.

 

Total Voting Rights

In compliance with the FCA's Disclosure Guidance and Transparency Rules, the Company announces that, as at today's date, it has 385,689,620 ordinary shares of 1 pence each in issue. The Company does not hold any shares in treasury and all of the ordinary shares have equal voting rights.

The figure of 385,689,620 ordinary shares represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

 

For further information, please contact:

CONTACTS

Cavendish (Management) Tel: +44 (0) 20 7220 0500

Julian Morse, Co-Chief Executive Officer investor.relations@cavendish.com

John Farrugia, Co-Chief Executive Officer

Ben Procter, Chief Financial Officer

 

SPARK Advisory Partners (Nominated Advisor)

Matt Davis / Adam Dawes Tel: +44 (0) 20 3368 3550

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRPPUMCMUPCGQA
12
Date   Source Headline
10th Apr 20263:18 pmRNSDirectors Dealings
1st Apr 20267:00 amRNSFull Year Trading Update
26th Feb 20263:38 pmRNSHolding(s) in Company
3rd Feb 20262:30 pmRNSDirectors Dealings
18th Dec 20259:08 amRNSDirectors Dealings
15th Dec 20254:15 pmRNSDirector Dealing: Correction
11th Dec 20254:00 pmRNSDirector Dealing
2nd Dec 20257:00 amRNSBlock Admission Return and Total Voting Rights
21st Nov 20254:45 pmRNSHolding(s) in Company
30th Oct 20257:00 amRNS2026 Interim Results
16th Oct 202510:23 amRNSDirector Dealing
1st Oct 20257:00 amRNSHalf Year Trading Update: Profitable First Half
16th Sep 202511:00 amRNSResult of AGM
29th Aug 20257:00 amRNSTotal Voting Rights
18th Jul 202512:07 pmRNSPosting of Annual Report and Notice of AGM
8th Jul 20254:39 pmRNSHolding(s) in Company
3rd Jul 202511:13 amRNS-RInvestor Presentation via Investor Meet Company
26th Jun 20257:00 amRNS2025 Full Year Results
24th Jun 202510:32 amRNSResponse to press speculation
2nd Jun 20257:00 amRNSBlock Admission Return and Total Voting Rights
27th May 20259:02 amRNSHolding(s) in Company
1st May 20254:56 pmRNSTotal Voting Rights
1st May 20254:55 pmRNSDirectors Dealings
9th Apr 20254:02 pmRNSDirector Dealing
4th Apr 20257:00 amRNSFull Year Trading Update
4th Feb 202512:39 pmRNSCompany Name Change
31st Jan 202511:26 amRNSDirectors Dealings
31st Jan 202511:22 amRNSDirector Dealings
12th Dec 20242:56 pmRNSDirectors Dealings
2nd Dec 20247:00 amRNSBlock Admission Return and Total Voting Rights
13th Nov 20243:00 pmRNSDirectors Dealings
11th Nov 20247:00 amRNS2025 Interim Results
21st Oct 20242:37 pmRNSDirectors Dealings
7th Oct 20247:00 amRNSHalf Year Trading Update: Profitable First Half
24th Sep 20249:20 amRNSIntended Purchases of Shares by EBT
16th Sep 202412:42 pmRNSResult of AGM
16th Sep 20249:09 amRNSAGM Trading Statement
6th Sep 20247:00 amRNSRule 19.6(c) Confirmation
15th Aug 20243:00 pmRNSDirectors Dealings
1st Aug 20248:44 amRNSPosting of Annual Report and Notice of AGM
26th Jul 20247:00 amRNSTotal Voting Rights
18th Jul 20244:33 pmRNSDirector Dealings
15th Jul 20247:00 amRNS2024 Full Year Results
12th Jun 20242:41 pmRNSHolding(s) in Company
24th May 20247:00 amRNSDirectorate Change
22nd Apr 202410:00 amRNSDirectors Dealings
8th Apr 20247:01 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSChange of Nominated Adviser
4th Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.